Company: DNLI
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001714899-25-000066
Chunk: 203

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 15
Chunk 203
---
 and Lonza Sales AG, dated December 8, 2020.10-K001-3831110.12.62/26/202110.12.7Amendment No. 7 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated March 29, 2021.10-K001-3831110.12.72/27/202310.12.8#Amendment No. 8 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 8, 2022.10-K001-3831110.12.82/27/202310.12.9Amendment No. 9 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated December 7, 2022.10-K001-3831110.12.92/27/202310.13+Amended and Restated Key Executive Change in Control and Severance Plan.10-Q001-3831110.611/5/202010.14+Executive Incentive Compensation Plan.S-1333-22152210.1411/13/201710.15+Amended and Restated Outside Director Compensation Policy.10-K001-3831110.152/28/202210.16#Option and Collaboration Agreement between the Registrant and Takeda Pharmaceutical Company Limited, dated January 3, 2018.10-K/A001-3831110.167/13/201810.17Common Stock Purchase Agreement between the Registrant and Takeda Pharmaceutical Company Limited, dated January 3, 2018.10-K001-3831110.173/19/201810.18Standstill and Stock Restriction Agreement between the Registrant and Takeda Pharmaceutical Company Limited, dated February 23, 2018.10-K001-3831110.183/19/201810.19First Amendment to Lease Agreement between the Registrant and HCP Oyster Point III LLC, dated May 2, 2018.10-Q001-3831110.18/9/201810.20ÜAmended and Restated Gamma IP License Agreement between the Registrant and F-star Gamma Limited, dated August 24, 2016.10-Q/A001-3831110.212/6/201810.21ÜSide Letter between the Registrant and F-star Gamma Limited, dated May 21, 2018.10-Q